PermeaDerm Study Shows Lower Costs, Comparable Wound Healing vs Allograft
PermeaDerm reduced product cost by 70% and preparation time by 95.7% compared with cadaveric allograft while achieving comparable clinical outcomes in a randomized study.
PermeaDerm reduced product cost by 70% and preparation time by 95.7% compared with cadaveric allograft while achieving comparable clinical outcomes in a randomized study.
New sizes for the Mia and Preserve systems expand the company’s minimally invasive breast offerings. The company also presented new clinical data on breast tissue preservation to more than 1,000 plastic surgeons.